MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ARGX stock logo

ARGX

argenx SE

$746.42
3.3
 (0.44%)
Exchange:  NASDAQ
Market Cap:  46.191B
Shares Outstanding:  15.705M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Timothy Van Hauwermeiren
Full Time Employees:  1599
Address: 
Laarderhoogtweg 25
Amsterdam
1101EB
NL
Website:  https://www.argenx.com
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/08 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,226,3162,190,2314,164,161.014
Gross Profit1,108,4811,962,9423,712,101.565
EBITDA-192,285105,171972,461.712
Operating Income-425,049-21,654972,461.712
Net Income-295,053833,0401,296,032.818

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets4,542,4586,202,5228,682,698
Total Liabilities444,951704,2391,359,606
Total Stockholders Equity4,097,5075,498,2837,323,092
Total Debt20,00039,05383,487
Cash and Cash Equivalents2,048,8441,499,9363,491,289

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-420,327-82,747850,485.457
Capital Expenditure-43,812-68,301-6,184.077
Free Cash Flow-464,139-151,048844,301.380
Net Income-425,049833,0401,296,032.818
Net Change in Cash1,248,104-548,9081,991,353

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)9,913,725.082Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)12,116,531.429Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)11,005,374.214Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-4,035,073.994Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-3,301,490.570Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-3,665,033.970Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)3,407,836.456Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)4,425,843.199Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)3,912,332.013Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)6,242,052.753Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)7,629,022.163Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)6,929,395.948Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)59.250Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)67.030Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)51.610Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)11Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)5Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
2.186B  ?P/S
 (TTM)
: 
14.65
?Net Income
 (TTM)
: 
831.568M  ?P/E
 (TTM)
: 
43.51
?Enterprise Value
 (TTM)
: 
46.078B  ?EV/FCF
 (TTM)
: 
62.03
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
0.17  ?ROIC
 (TTM)
: 
0.12
?Net Debt
 (TTM)
: 
-3339773000  ?Debt/Equity
 (TTM)
: 
0.01
?P/B
 (TTM)
: 
6.71  ?Current Ratio
 (TTM)
: 
5.23

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
21.28Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate ARGX Intrinsic Value

Common questions about ARGX valuation

Is argenx SE (ARGX) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for argenx SE (ARGX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ARGX a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ARGX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ARGX’s P/E ratio?

You can see ARGX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ARGX?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ARGX a good long-term investment?

Whether ARGX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ARGX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

0.44
MARKETSnap

Trading Metrics:

Open: 738.53   Previous Close: 743.12
Day Low: 735.68   Day High: 759.89
Year Low: 510.06   Year High: 934.62
Price Avg 50: 774.54   Price Avg 200: 755.84
Volume: 366886   Average Volume: 363913

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Allspring Global Investments Holdings LLC Sells 38,598 Shares of argenex SE $ARGX
31-03-2026 03:22
Allspring Global Investments Holdings LLC Sells 38,598 Shares of argenex SE $ARGX
eClinical Solutions elluminate® Platform Supports argenx to Enhance Data Oversight and Efficiency
24-03-2026 09:00
eClinical Solutions elluminate® Platform Supports argenx to Enhance Data Oversight and Efficiency
These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
27-02-2026 08:48
These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
Artisan Partners Limited Partnership Sells 163,266 Shares of argenex SE $ARGX
27-02-2026 03:16
Artisan Partners Limited Partnership Sells 163,266 Shares of argenex SE $ARGX
argenx SE (ARGX) Q4 2025 Earnings Call Transcript
26-02-2026 12:57
argenx SE (ARGX) Q4 2025 Earnings Call Transcript
Argenx Touts Positive Phase 3 Eye Disease Study Results
26-02-2026 09:01
Argenx Touts Positive Phase 3 Eye Disease Study Results

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read